Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment Facilities

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how COVID-19 drastically changed his institution and what has been implemented to keep providers and patients safe.

Transcript:

COVID-19 has really changed how we think and how we’ve done everything. We never closed [my institution], but we did a lot of telemedicine visits; we still are, but not as much as before. [COVID-19 has] affected everything from our research program to our patients. Most importantly, it’s affected the patients because we’ve limited visitors for obvious reasons. This has been a harder time for the patients and their loved ones to not have somebody with them when they’re in clinic getting their infusion. We’ve all at this point become accustomed to it. We’re all masked up, I’ve got mine sitting right next to me. It’s just been tough and challenging. We’ve all evolved [but] it’ll be great to get back to normal at some point, though.

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content